Eliana Clark - Jul 3, 2023 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Role
EVP, Chief Technical Officer
Signature
/s/ Glenn Goddard, attorney-in-fact
Stock symbol
NTLA
Transactions as of
Jul 3, 2023
Transactions value $
-$14,584
Form type
4
Date filed
7/6/2023, 03:34 PM
Previous filing
Jun 22, 2023
Next filing
Jan 5, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NTLA Common Stock Sale -$14.6K -360 -0.79% $40.51 45.1K Jul 3, 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Sale of 360 shares that were acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2023.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.51 to $40.52, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 3, 2023 at each separate price.